Cancer drug discovery business Sareum Holdings has been offered a grant from funding programme Biomedial Catalyst, which will provide financial support for the company's Fatty Acid Synthase (FASN) research programme.
The £150,000 grant funding will enable Sareum to explore further the potential of its novel chemical series, which shows promising efficacy in breast cancel cell models, over the next nine months.
Sareum will receive the grant on the condition it contributes up to £50,000 from its working capital during the funding period, as well as a compliance review by the Technology Strategy Board and an agreement between both parties.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sareum's Chief Executive, Dr. Tim Mitchell, said: "We are delighted to have been offered this financial support from the Biomedical Catalyst, which gives us the opportunity to demonstrate the potential of our novel FASN inhibitors.
"Success from this funding period may open up the opportunity of additional awards to advance further the programme. We believe this award is a positive validation of Sareum's science as competition for these grants is very strong."
The share price climbed 2.% to 1.02p by 09:37.
NR
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
